Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460159 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP1A1CYP1A2 | |
| SCHEMBL19779541 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP1A1CYP1A2 | |
| SCHEMBL14367734 | 0.94 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP1A1CYP1A2 | |
| SCHEMBL22402148 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP1A1CYP1A2 | |
| SCHEMBL5473307 | 0.77 | TSHR (0.35) | — | |
| SCHEMBL7735127 | 0.77 | TSHR (0.35) | — | |
| SCHEMBL14012881 | 0.77 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP1A1CYP1A2 | |
| SCHEMBL27483884 | 0.74 | TSHR (0.34) | CYP1A2CYP2D6CYP3A4KCNH2CYP2C19 | |
| SCHEMBL11863846 | 0.74 | TSHR (0.34) | CYP1A2CYP2D6CYP3A4KCNH2CYP2C19 | |
| SCHEMBL6784146 | 0.74 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | SLC6A2 2383/4885SLC6A4 1829/4885SLC6A3 2272/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | SLC6A2 2033/4885SLC6A4 1616/4885SLC6A3 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.